FDA Brief

Warning letters Drugs

FDA warning letter to

Antonio E. Blanco, M.D./Vista Health Research, LLC

High riskIssued Sep 26, 2023Posted Oct 10, 2023Center for Drug Evaluation and Research | CDER

FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.

What happened

FDA inspected the Miami clinical site from January 11 to January 30, 2023, under its Bioresearch Monitoring Program. FDA found subjects enrolled without protocol-required eligibility documentation, a subject randomized without required e-Diary entries, and protocol-required safety imaging visits missed. The investigator's February 17, 2023 response was inadequate because it lacked supporting documentation and sufficient corrective-action details.

What FDA found

  1. Failed to ensure the clinical investigation was conducted according to the investigational plan.

    21 CFR 312.60
  2. Randomized subjects without documented surgical diagnosis within 10 years before screening, as the protocol required, and gave them multiple doses of investigational drug.

    21 CFR 312.60
  3. Randomized a subject without the protocol-required electronic diary documentation.

    21 CFR 312.60
  4. Did not perform protocol-required safety imaging at specified study visits for three subjects.

    21 CFR 312.60

What FDA wants

Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. Include sufficient details about corrective actions and any planned or completed training.

Who should pay attention

  • clinical trial sponsors and CROs
  • research sites and investigators
  • IRBs overseeing drug trials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  3. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  4. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk